Ovid Therapeutics Inc.
OVID
$1.11
$0.087.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 6.27M | 130.00K | 76.00K | 173.00K | 169.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.27M | 130.00K | 76.00K | 173.00K | 169.00K |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 6.27M | 130.00K | 76.00K | 173.00K | 169.00K |
| SG&A Expenses | 4.88M | 6.02M | 6.78M | 5.54M | 8.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.35M | 12.68M | 11.00M | 13.40M | 20.69M |
| Operating Income | -5.07M | -12.55M | -10.92M | -13.23M | -20.52M |
| Income Before Tax | -4.68M | -10.24M | -9.25M | -14.01M | 8.52M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.68M | -10.24M | -9.25M | -14.01M | 8.52M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.68M | -10.24M | -9.25M | -14.01M | 8.52M |
| EBIT | -5.07M | -12.55M | -10.92M | -13.23M | -20.52M |
| EBITDA | -4.97M | -12.41M | -10.76M | -13.06M | -20.37M |
| EPS Basic | -0.06 | -0.14 | -0.12 | -0.20 | 0.12 |
| Normalized Basic EPS | -0.04 | -0.11 | -0.08 | -0.12 | 0.07 |
| EPS Diluted | -0.06 | -0.14 | -0.13 | -0.20 | 0.12 |
| Normalized Diluted EPS | -0.04 | -0.11 | -0.08 | -0.12 | 0.07 |
| Average Basic Shares Outstanding | 71.11M | 71.05M | 71.01M | 70.98M | 70.92M |
| Average Diluted Shares Outstanding | 71.11M | 71.05M | 71.01M | 70.98M | 71.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |